RS59914B1 - Metode sa oligonukleotidnim helatnim kompleksom - Google Patents
Metode sa oligonukleotidnim helatnim kompleksomInfo
- Publication number
- RS59914B1 RS59914B1 RS20200065A RSP20200065A RS59914B1 RS 59914 B1 RS59914 B1 RS 59914B1 RS 20200065 A RS20200065 A RS 20200065A RS P20200065 A RSP20200065 A RS P20200065A RS 59914 B1 RS59914 B1 RS 59914B1
- Authority
- RS
- Serbia
- Prior art keywords
- chelate complex
- complex methods
- oligonucleotide chelate
- oligonucleotide
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648694P | 2012-05-18 | 2012-05-18 | |
PCT/CA2013/050378 WO2013170385A1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex methods |
EP13791584.9A EP2849760B1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex methods |
Publications (1)
Publication Number | Publication Date |
---|---|
RS59914B1 true RS59914B1 (sr) | 2020-03-31 |
Family
ID=49581827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20200065A RS59914B1 (sr) | 2012-05-18 | 2013-05-17 | Metode sa oligonukleotidnim helatnim kompleksom |
Country Status (37)
Country | Link |
---|---|
US (1) | US9616083B2 (sr) |
EP (1) | EP2849760B1 (sr) |
JP (2) | JP6294308B2 (sr) |
KR (1) | KR101975915B1 (sr) |
CN (1) | CN104379152B (sr) |
AR (1) | AR091065A1 (sr) |
AU (1) | AU2013262415B2 (sr) |
BR (1) | BR112014028568B1 (sr) |
CA (1) | CA2873526C (sr) |
CL (1) | CL2014003135A1 (sr) |
CO (1) | CO7131388A2 (sr) |
CR (1) | CR20140522A (sr) |
CU (1) | CU20140132A7 (sr) |
CY (1) | CY1122856T1 (sr) |
DK (1) | DK2849760T3 (sr) |
DO (1) | DOP2014000263A (sr) |
EA (1) | EA034799B1 (sr) |
EC (1) | ECSP14027542A (sr) |
ES (1) | ES2767333T3 (sr) |
HK (1) | HK1206259A1 (sr) |
HR (1) | HRP20200045T1 (sr) |
HU (1) | HUE047456T2 (sr) |
IL (1) | IL235402B (sr) |
IN (1) | IN2014DN08982A (sr) |
LT (1) | LT2849760T (sr) |
MX (1) | MX360626B (sr) |
MY (1) | MY168209A (sr) |
NZ (1) | NZ701931A (sr) |
PH (1) | PH12014502484A1 (sr) |
PL (1) | PL2849760T3 (sr) |
PT (1) | PT2849760T (sr) |
RS (1) | RS59914B1 (sr) |
SG (1) | SG11201407261XA (sr) |
SI (1) | SI2849760T1 (sr) |
TW (1) | TWI648288B (sr) |
WO (1) | WO2013170385A1 (sr) |
ZA (1) | ZA201408082B (sr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2914775T3 (es) | 2007-10-26 | 2022-06-16 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarresta trastornos del músculo |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
ES2907250T3 (es) | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker |
BR112015003985A2 (pt) | 2012-08-30 | 2017-08-08 | Replicor Inc | métodos para tratamento de infecções de hepatite b e hepatite d |
MA42569B1 (fr) | 2015-04-23 | 2020-08-31 | Geron Corp | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
EP3368063B1 (en) | 2015-10-28 | 2023-09-06 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
US11534451B2 (en) | 2015-12-23 | 2022-12-27 | Repluca Pty Ltd | Nucleic acid oligomers and uses therefor |
US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
WO2022229350A2 (en) | 2021-04-30 | 2022-11-03 | Tirmed Pharma Ab | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022488A1 (en) * | 1993-04-01 | 1994-10-13 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION |
US20020166764A1 (en) * | 1997-08-12 | 2002-11-14 | University Of Southern California | Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes |
US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2330194A3 (en) * | 2002-09-13 | 2011-10-12 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
CN1694959A (zh) * | 2002-09-13 | 2005-11-09 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
AU2005297376A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
EP1942911A4 (en) | 2005-09-29 | 2009-08-19 | Replicor Inc | THERAPEUTIC MOLECULES AND USES THEREOF |
JP2010500290A (ja) * | 2006-08-04 | 2010-01-07 | アイシス ファーマシューティカルズ, インコーポレーテッド | Jnkタンパク質を調節するための組成物および方法 |
WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
AU2009221064B2 (en) | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US9107933B2 (en) | 2009-03-16 | 2015-08-18 | Isis Pharmaceuticals, Inc. | Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III |
CN103221541B (zh) * | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
NZ606364A (en) * | 2010-08-20 | 2014-12-24 | Replicor Inc | Oligonucleotide chelate complexes |
-
2013
- 2013-05-16 AR ARP130101695A patent/AR091065A1/es not_active Application Discontinuation
- 2013-05-17 JP JP2015511876A patent/JP6294308B2/ja active Active
- 2013-05-17 RS RS20200065A patent/RS59914B1/sr unknown
- 2013-05-17 IN IN8982DEN2014 patent/IN2014DN08982A/en unknown
- 2013-05-17 AU AU2013262415A patent/AU2013262415B2/en active Active
- 2013-05-17 TW TW102117593A patent/TWI648288B/zh active
- 2013-05-17 BR BR112014028568-3A patent/BR112014028568B1/pt active IP Right Grant
- 2013-05-17 MY MYPI2014003113A patent/MY168209A/en unknown
- 2013-05-17 LT LTEP13791584.9T patent/LT2849760T/lt unknown
- 2013-05-17 PT PT137915849T patent/PT2849760T/pt unknown
- 2013-05-17 CN CN201380025475.XA patent/CN104379152B/zh active Active
- 2013-05-17 NZ NZ701931A patent/NZ701931A/en unknown
- 2013-05-17 US US13/896,427 patent/US9616083B2/en active Active
- 2013-05-17 PL PL13791584T patent/PL2849760T3/pl unknown
- 2013-05-17 KR KR1020147035251A patent/KR101975915B1/ko active IP Right Grant
- 2013-05-17 MX MX2014013885A patent/MX360626B/es active IP Right Grant
- 2013-05-17 EP EP13791584.9A patent/EP2849760B1/en active Active
- 2013-05-17 SI SI201331646T patent/SI2849760T1/sl unknown
- 2013-05-17 EA EA201401276A patent/EA034799B1/ru unknown
- 2013-05-17 ES ES13791584T patent/ES2767333T3/es active Active
- 2013-05-17 DK DK13791584.9T patent/DK2849760T3/da active
- 2013-05-17 WO PCT/CA2013/050378 patent/WO2013170385A1/en active Application Filing
- 2013-05-17 CA CA2873526A patent/CA2873526C/en active Active
- 2013-05-17 HU HUE13791584A patent/HUE047456T2/hu unknown
- 2013-05-17 SG SG11201407261XA patent/SG11201407261XA/en unknown
-
2014
- 2014-10-30 IL IL235402A patent/IL235402B/en unknown
- 2014-11-04 ZA ZA2014/08082A patent/ZA201408082B/en unknown
- 2014-11-06 PH PH12014502484A patent/PH12014502484A1/en unknown
- 2014-11-14 CR CR20140522A patent/CR20140522A/es unknown
- 2014-11-17 CU CU2014000132A patent/CU20140132A7/es unknown
- 2014-11-17 EC ECIEPI201427542A patent/ECSP14027542A/es unknown
- 2014-11-18 DO DO2014000263A patent/DOP2014000263A/es unknown
- 2014-11-18 CL CL2014003135A patent/CL2014003135A1/es unknown
- 2014-11-19 CO CO14254326A patent/CO7131388A2/es unknown
-
2015
- 2015-07-20 HK HK15106885.8A patent/HK1206259A1/xx unknown
-
2017
- 2017-11-02 JP JP2017212508A patent/JP2018058853A/ja active Pending
-
2020
- 2020-01-13 HR HRP20200045TT patent/HRP20200045T1/hr unknown
- 2020-01-21 CY CY20201100051T patent/CY1122856T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254716B (en) | Zinc-lysine conjugate | |
HK1250690A1 (zh) | 方法 | |
DK2922554T3 (en) | Terminalt modificeret rna | |
HK1208363A1 (en) | New methods | |
HK1206259A1 (en) | Oligonucleotide chelate complex methods | |
GB2507760B (en) | Methods | |
ZA201408674B (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
EP2852660A4 (en) | PROCESS | |
GB201208874D0 (en) | Methods | |
EP2891717A4 (en) | Oligonucleotide | |
GB201204280D0 (en) | Methods | |
GB201208756D0 (en) | Methods | |
GB201220686D0 (en) | Methods | |
AP2012000550S (en) | E-horn methods | |
GB201216074D0 (en) | Methods | |
GB201209689D0 (en) | Methods | |
GB201208875D0 (en) | Methods | |
GB201208963D0 (en) | Methods | |
GB201207793D0 (en) | Methods | |
GB201209932D0 (en) | Improved process | |
GB201202052D0 (en) | Well cementation | |
GB201205665D0 (en) | Process | |
GB201205052D0 (en) | Process |